NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Aptorum Group Ltd (APM) Stock Analysis

Aptorum Group Ltd (APM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

APM

$8.41

+$0.03 (+0.36%)

Last trade July 27, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APM with… →

APM Key Statistics

As of Jul 27, 2026
Trading
Open
$8.02
Previous Close
$8.38
Day's Range
7.80–8.82
52-Week Range
0.60–44.70
Volume
34.54K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.17
Valuation
Market Cap
$570.06K
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.90
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$1.36M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+364.64%
Dividend and dates
Avg Volume
79.44K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

APM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+693.40%
2025−23.74%

As of July 27, 2026.

APM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$1.36M—
2024$0.00−$4.27M—
2023$431.38K−$2.82M−654.8%
2022$1.30M−$9.80M−756.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00$0.00−$1.82M−$1.36M—
2024$0.00$0.00−$3.00M−$4.27M—
2023$431.38K$10.57K−$10.60M−$2.82M−654.8%
2022$1.30M$80.07K−$17.17M−$9.80M−756.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

APM Valuation vs Biotechnology Median

Median of 656 stocks
MetricAPMBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Aptorum Group Ltd (APM) is capitalised at $570.06K on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 1.

Over the past 52 weeks the price has ranged from $0.60 to $44.70. APM last closed at $8.41 on July 27, 2026. That is +$0.03 (+0.36%) against the previous close. The latest close sits 1,301.67% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $1.36M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.9.

Across the 4 fiscal years on file, revenue moves from $1.30M in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year price return is +364.64%. The stored price history starts on January 10, 2025, and the total return since then is +505.04%. The reported beta is 0.17. Annualized volatility over the trailing 1 year is 951.36%.

Growth & Income

No dividend is on file for APM.

2026 is still running; the price is +693.40% year to date. The record holds one complete calendar year, 2025, which returned −23.74%.

Peer Comparison

Aptorum Group Ltd (APM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aptorum Group Ltd APM $570.06K —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Aptorum Group Ltd has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 27, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Aptorum Group Ltd

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

Visit website →